Helicobacter pylori eradication therapy with Vonoprazan, reduced dosage of amoxicillin, and clarithromycin for hemodialysis patients

Efficacy and safety of Helicobacter pylori eradication therapy with Vonoprazan, reduced dosage of amoxicillin, and clarithromycin for patients on dialysis for renal failure

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031200237

Enrollment

Registered

2020-12-11

Start date

2023-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection Helicobacter pylori

Interventions

Vonoprazan (20mg), amoxicillin (250mg), and clarithromycin (200mg) given on twice daily for 7days

Helicobacter pylori eradication therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients infected with Helicobacter pylori. Positive patients by Urea breath test, stool Helicobacter pylori antigen test, anti-Helicobacter pylori antibody test (blood), Helicobacter pylori culture are treated with infected. Patients diagnosed as chronic gastritis, gastroduodenal ulcer, MALT lymphoma, idiopathic thrombocytopenic purpura, or after endoscopic treatment of early gastric cancer, and performed upper gastrointestinal endoscopy within a year. Hemodialysis patients for end-stage renal failure. Patients who give a written informed consent.

Exclusion criteria

Exclusion criteria: Patients who have Helicobacter pylori eradication history. Pregnancy or lactation. Patients using stazanavir, rilpivirine, pimozide, ergotamine, suvorexant, lomitapide mesylate, tadalafil, ticagrelor, ibrutinib, asuna previr, ivavradine, venetoclax, lurasidone hydrochloride, anamorelin hydrochloride, finerenone, isavuconazonium sulfate, or colchicine. Patients who are disqualified for the study by physicians.

Design outcomes

Primary

Measure	Time frame
Eradication rate (PPS)	—

Secondary

Measure	Time frame
(1) Eradication rate (PPS) (2) Safety	—

Contacts

Public ContactSue Soichiro

Yokohama City University Hospital

ssue@yokohama-cu.ac.jp+81-457872800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026